Showing results (11-20 of 21) with videos related to
Sort By:
Pageof 3
The Lancet. Oncology|February 13, 2010
Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 studyDavid Thomas, Robert Henshaw, Keith Skubitz, et al.Lancet (London, England)|March 1, 2011
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind studyKarim Fizazi, Michael Carducci, Matthew Smith, et al.Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 29, 2013
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumorsDavid Henry, Saroj Vadhan-Raj, Vera Hirsh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 18, 2013
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling timeMatthew R Smith, Fred Saad, Stephane Oudard, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 10, 2010
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyAlison T Stopeck, Allan Lipton, Jean-Jacques Body, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 16, 2012
Bone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acidMiguel Martin, Richard Bell, Hugues Bourgeois, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2011
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myelomaDavid H Henry, Luis Costa, Francois Goldwasser, et al.Cancer|September 7, 2012
Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acidCharles S Cleeland, Jean-Jacques Body, Alison Stopeck, et al.Lancet (London, England)|November 19, 2011
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trialMatthew R Smith, Fred Saad, Robert Coleman, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2003
Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseasesRichard A Nash, Roger Dansey, Jan Storek, et al.Pageof 3